Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib

Curing CLL: one clone at a time

“…The median time to progression was 14 cycles for the mutant cohort and 22 cycles for the wild-type cohort. 9 These data implicate that the existence of any BTK mutation imposes an increased risk and velocity of progression during treatment with pirtobrutinib. However, not all patients with disease progression exhibited clonal BTK evolution, with the disappearance of the original clone.…”

“…Ex vivo pharmacological profiling of CLL cells at DP or during pirtobrutinib-based therapy showed that venetoclax and APR-246 (a glutathione modulator) were the most effective agents alone and in combination with BTKi. 9 Several key therapeutic questions have emerged from these observations. Does the disease become more sensitive to cBTKi when the C481S clone is abolished?…”